Sana Biotechnology, Inc. (SANA)

NASDAQ • Healthcare

$2.33

-$0.04 (-1.7%)

Market open

Last close at October 23, 2026 at 20:00 UTC

Open$2.35

Previous Close$2.33

Day Range$2.25 - $2.38

Avg. Volume (3M)3.2M

Market Cap$697.5M

52 Week Range

$2.22$5.7

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)

Net Income (TTM)

-$211.8M

EPS (TTM)

-$0.76

ROA (TTM)

-49.09%

Current Ratio

1.38

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

-95.0%Q3 2025-$0.39

+16.7%Q4 2025-$0.15

-23.1%Q1 2026-$0.16

+6.7%Q2 2026-$0.14

-49.8%Q3 2026-$0.22

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Miss -49.8%

Sana Biotechnology’s preliminary results for the second fiscal quarter of 2026 trailed consensus on EPS, with the company reporting -$0.22 versus an estimate of -$0.15 (difference -$0.07), alongside a GAAP net loss that narrowed year over year; the quarter was reported August 11, 2026. Net income improved ~32% to a loss of about $63.6 million, up from a loss of about $93.8 million a year ago, while operating income came in at a loss of roughly $65.4 million. The reported EPS loss of -$0.22 also improved ~44% from -$0.39 a year earlier, despite trailing the Street’s estimate for the quarter. Cash flow from operations was negative, at roughly -$32.8 million. For the next period, consensus calls for EPS of -$0.18.

Next report — what to expect

Sana Biotechnology, Inc. (SANA) reports next on November 5, 2026. Wall Street’s consensus calls for EPS of -$0.148. Recent results have been mixed, with Sana beating EPS in 5 of its 8 most recent quarters, making any updates to pipeline progress and cash runway key items for traders to watch.

View full earnings history

About Sana Biotechnology, Inc.

Sana Biotechnology, Inc. (NASDAQ: SANA) is a small-cap biotechnology company developing treatments built from engineered cells. Founded in 2018, Sana works through advanced ex vivo and in vivo cell engineering platforms, using engineered cells to create therapies, and it has traded publicly since its 2021 NASDAQ listing.

Name

Sana Biotechnology, Inc.

CEO

Steven D. Harr

Website

www.sana.com

Industry

Healthcare

Year Founded

2018

Employees

142

Today's Snapshot

AI-generated

SANA closed 1.7% below yesterday's close, in line with a weaker sector. Trading was lighter than usual, with volume about half of its usual level. SANA is due to report earnings on 5 November.

Trading Volume

Below 10d avg (2.9M)

1.6M

vs S&P 500 Today

Underperforming Market

-1.17%

Updated: October 23, 2026 at 20:09 UTC

Technical Indicators

1 Buy1 Neutral6 Sell

SANA exhibits pronounced technical deterioration, trading well below its major moving averages and under a 200-day near 3.45 while the current price is about 2.33, which signals a clear longer-term down bias. ADX above 32 indicates a strong downward trend, and momentum measures and MACD are negative, even as some oscillators show oversold levels. Volatility is elevated with an ATR near 7.5%, and on-balance volume is deeply negative, highlighting distribution. The classic pivot sits above the market, acting as resistance. Technical takeaway: Strong Sell — strong downtrend, rising volatility and heavy selling pressure.

All signals